A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
The study had the following primary objectives:
- Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib
and dexamethasone for patients with relapsed or refractory multiple myeloma who have
received 1 to 3 prior therapies
- Phase 2: to estimate the overall response rate (ORR) for patients with relapsed or
refractory multiple myeloma who received 1 to 3 prior therapies treated with carfilzomib
and dexamethasone QW at the MTD established in phase 1.